← Leaderboards
Thanh Uyen Barbie
Dana-Farber Cancer Inst
$2,007,374
Attributed
$2,007,374
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $407.2K · FY2021–25$500K$375K$250K$125K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,007,374 · 1
By mechanism
R01$2,007,374 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Franziska Michor$16,040,992
- Kornelia Polyak$28,582,691
- Kosj Yamoah$3,600,679
- Alexander H. Stegh$12,620,634
- Timothy R Rebbeck$50,819,475
Others in their field
Other Emerging Leaders on “Effective Therapy”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$69,114,853
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Yunda Huang · Fred Hutchinson Cancer Center$51,679,442
Research focus
Effective TherapyEvidence BaseAnti-Pd1 TherapyDs-DnaAnalogDrug UsageBreast BiopsyBreast Cancer Cell LineAgonistDrug KineticsBreast MalignanciesCancer CellCancer ImmunotherapyCellsClinical ApplicationClinically ActionableClinical TranslationClinical TrialsBreast Cancer ModelCytokineBreast Cancer PreventionDinucleoside PhosphatesDrug Delivery SystemsExodeoxyribonuclease
Grant awards (5)
Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer$407,175
R01 · FY2025 · CA · contact PI
Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer$386,817
R01 · FY2024 · CA · contact PI
Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer$399,032
R01 · FY2023 · CA · contact PI
Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer$407,175
R01 · FY2022 · CA · contact PI
Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer$407,175
R01 · FY2021 · CA · contact PI